Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells

Alectinib is a new generation ALK inhibitor with activity against the gatekeeper L1196M mutation that showed remarkable activity in a phase I/II study with echinoderm microtubule associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) non-small cell lung cancer (NSCLC) patients. However,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tanimoto, Azusa, Yamada, Tadaaki, Nanjo, Shigeki, Takeuchi, Shinji, Ebi, Hiromichi, Kita, Kenji, Matsumoto, Kunio, Yano, Seiji
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148110/
https://ncbi.nlm.nih.gov/pubmed/24952482
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky